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Abstract
Background: The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244,
ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown
clinical activity as monotherapy in phase I and II studies of advanced cancer. Preclinical data suggest that selumetinib
may enhance the activity of chemotherapeutic agents. We assessed the safety, tolerability, and pharmacokinetics (PK)
of selumetinib (AZD6244, ARRY-142886) in combination with docetaxel or dacarbazine in patients with advanced solid
tumors.
Methods: This study was a phase I, open-label, multicenter study in patients aged ≥18 years with advanced solid tumors
who were candidates for docetaxel or dacarbazine treatment. Part A of the study (dose escalation) evaluated safety,
tolerability, PK, and maximum tolerated dose (MTD) of selumetinib twice daily (BID) with docetaxel 75 mg/m2 or
dacarbazine 1000 mg/m2 administered every 21 days. Patients receiving docetaxel could be administered primary
prophylactic granulocyte-colony stimulating factor according to standard guidelines. Part B of the study (dose expansion)
further evaluated safety, tolerability, and PK in 12 additional patients at the MTD combinations determined in part A.
Results: A total of 35 patients received selumetinib plus docetaxel, and 25 received selumetinib plus dacarbazine. The
MTD of selumetinib was 75 mg BID in combination with either docetaxel (two dose-limiting toxicity [DLT] events:
neutropenia with fever, and thrombocytopenia) or dacarbazine (one DLT event: thrombocytopenia). Common adverse
events occurring with each treatment combination were diarrhea, peripheral/periorbital edema, fatigue, and nausea. PK
parameters for selumetinib and docetaxel or dacarbazine were similar when administered alone or in combination. Partial
responses were reported in 6/35 patients receiving selumetinib plus docetaxel and 4/25 patients receiving selumetinib
plus dacarbazine.
Conclusions: The combinations of selumetinib plus docetaxel and selumetinib plus dacarbazine demonstrated
manageable safety and tolerability profiles and preliminary signs of clinical activity in patients with advanced solid tumors.
Trial registration: ClinicalTrials.gov NCT00600496; registered 8 July 2009.
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Background
The intracellular RAS/RAF/MEK/ERK pathway converges
on MEK1/2, of which the only known substrates are
ERK1/2. Constitutive activation of the pathway is impli-
cated in cell proliferation and is central to driving cancer
growth and progression [1, 2]. The integral role of MEK1/
2 in this signaling cascade highlights its potential as a
therapeutic target. Selumetinib (AZD6244, ARRY-142886)
is an oral, potent, and highly selective, allosteric MEK1/2
inhibitor [3] with a short half-life [4, 5]. Clinical activity of
selumetinib monotherapy in some patients with advanced
solid tumors has been reported in phase I [4, 6] and phase
II studies [7–10], and the recommended dose for selume-
tinib monotherapy is 75 mg twice daily (BID). The poten-
tial benefit of combining MEK inhibitors with
chemotherapy has been demonstrated in preclinical studies
of tumor xenograft models, in which selumetinib in com-
bination with cytotoxic agents, such as docetaxel or the
dacarbazine derivative temozolomide, showed enhanced
tumor growth inhibition compared with selumetinib
monotherapy, or chemotherapy alone [1, 11]. Selumetinib
plus docetaxel in previously treated patients with KRAS-
mutant advanced non-small cell lung cancer (NSCLC)
[12], and selumetinib plus dacarbazine in patients with
BRAF-mutant metastatic melanoma [13], have more re-
cently been assessed in phase II trials. Additional phase II
and phase III trials of selumetinib plus docetaxel in
advanced NSCLC were also initiated (ClinicalTrials.gov
identifiers: NCT01750281; NCT01933932). Here we
present the phase I study on which development of these
combinations was based.
The objectives of this four-arm dose-escalation study
were to assess the safety, tolerability, pharmacokinetics
(PK), and maximum tolerated dose (MTD) of selumetinib
in combination with selected anticancer therapies (doce-
taxel, dacarbazine, erlotinib, or temsirolimus) in patients
with advanced solid tumors. An exploratory assessment of
tumor response was also conducted. A single-institution
assessment of patients with metastatic melanoma enrolled
in this study has previously been reported [14]. In consid-
eration of the notable differences in safety and tolerability
profiles when combining selumetinib with different classes
of cancer therapeutics, we present here data from 60 pa-
tients who received selumetinib in combination with cyto-
toxic agents (docetaxel or dacarbazine). Results for those
patients who received selumetinib in combination with
other molecularly targeted therapies (erlotinib or temsiro-
limus) are presented by Infante et al. in a companion
manuscript (in preparation).
Methods
This phase I, open-label, multicenter, dose-escalation
study (NCT00600496) was conducted at four centers in
the USA between December 2007 and August 2010
(data cut-off occurring 6 months after the last patient
began treatment).
Patient selection
Patients with advanced solid tumors who would be
candidates for docetaxel or dacarbazine treatment as a
standard of care, or those who might have derived benefit
from combination therapies with these agents, were eli-
gible for the study. Other eligibility criteria included: age
≥18 years; measurable and/or non-measurable disease
lacking curative options; World Health Organization
(WHO) performance status 0 or 1; and calculated serum
creatinine clearance >50 mL/min.
Patients meeting any of the following criteria were
excluded from the study: prior treatment with a MEK in-
hibitor; received an investigational drug within 30 days of
entering the study, and/or had not recovered to < grade 1
toxicity; received radiotherapy or standard chemotherapy
within 21 days of study entry; use of strong cytochrome
(CYP)1A2 or 3A4 inducers and/or inhibitors; brain metas-
tases or spinal cord compression unless treated and stable
(>1 month) and off steroids; having factors that increased
the risk of QT prolongation or arrhythmic events or QTc
interval of >450 ms for males or >470 ms for females; or
inadequate bone marrow, hepatic, cardiac, or renal
function.
All patients provided written informed consent and the
study was conducted in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki. The
protocol was approved by the institutional review board at
each study site (Additional file 1: Table S1).
Study design and dosing
For each treatment arm, the study was conducted in two
parts: part A (dose escalation) enrolled cohorts of three to
six evaluable patients and assessed the safety, tolerability,
PK, and MTD of selumetinib in combination with either
docetaxel or dacarbazine; part B (dose expansion) further
evaluated the safety, tolerability, and PK in a minimum of
12 additional patients at the MTDs for combination treat-
ments determined in part A. The study safety review com-
mittee (SRC), comprising representatives from the study
sponsor and at least one investigator, assessed the available
safety and PK data. Dose-limiting toxicities (DLTs) in the
study were defined as those related to treatment and oc-
curring within the first 28 days of therapy. Hematologic
DLTs were defined as afebrile grade 4 neutropenia for
>5 days, grade 4 neutropenia associated with fever, or
grade 4 thrombocytopenia. Non-hematological DLTs were
defined as any ≥ grade 3 adverse event (AE) for >7 days
that could not be controlled to grade ≤2 with appropriate
treatment.
Patients received intravenous docetaxel 75 mg/m2 or
dacarbazine 1000 mg/m2 over 60 mins on day 1 of each
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21-day cycle. Selumetinib was initiated BID, orally, be-
ginning on day 3 of cycle 1. Patients could remain on
combination treatment or selumetinib monotherapy
after discontinuation of chemotherapy, providing they
were continuing to derive clinical benefit, until disease
progression or intolerable AEs occurred. Patients receiv-
ing docetaxel could be administered primary prophylac-
tic granulocyte-colony stimulating factor (ppG-CSF),
including pegylated G-CSF, according to standard
guidelines.
Dose exploration commenced at the starting dose level
of selumetinib 50 mg BID. Patients were enrolled into part
A in initial cohorts of three to six patients and subsequent
dose levels were determined by the SRC, which reviewed
the emerging tolerability and safety profile on an ongoing
basis, and upon completion of each dose level cohort. In
addition, the predicted exposure to selumetinib at each
dose level evaluated was not to exceed the exposures
previously observed at the monotherapy MTD of 75 mg
BID [4]. Patients were considered evaluable if they had
received at least 28 days of therapy from cycle 1/day 1, re-
ceived approximately 80% of the planned doses of selume-
tinib, had experienced a DLT, or at the discretion of the
SRC. The combination MTD in this study was defined as
the highest selumetinib dose achieved at which no more
than one of six evaluable patients experienced a DLT. In
part B (dose expansion) of the study, an additional 12




Safety assessments included: all AEs graded using National
Cancer Institute Common Terminology Criteria for Ad-
verse Events (CTCAE) version 3.0; vital signs (including
blood pressure, pulse rate, weight, and body temperature);
electrocardiogram; Multi-Gated Acquisition (MUGA) scan;
clinical chemistry; brain natriuretic peptide; troponin I;
hematology; urinalysis; and ophthalmologic examinations.
Incidence of DLTs was also recorded.
Pharmacokinetics assessments
Pharmacokinetic parameters of selumetinib, N-
desmethyl selumetinib, docetaxel, and dacarbazine were
determined following administration of each drug alone
and in combination. Blood sampling was performed pre-
dose and after chemotherapy infusion as follows: cycle
1/day 1 (selumetinib) and cycle 2/day 1 (combination)
for measurement of docetaxel or dacarbazine levels; and
cycle 1/day 3 (selumetinib) and cycle 2/day 1
(combination).
Maximum plasma concentration (Cmax) and time to
reach the Cmax (Tmax) were determined on day 1, 3, and
22 of cycle 1 for docetaxel or dacarbazine, and day 3 and
22 of cycle 1 for selumetinib. Area under the plasma
concentration-time curve from 0 to 12 h post dose
(AUC(0–12)) was calculated using the linear trapezoidal
rule. When more than one maximum occurred, the re-
ported value was assigned to the first occurrence.
Tumor response
Objective tumor response was assessed according to
Response Evaluation Criteria In Solid Tumours (RECIST)
(version 1.0) with baseline tumor assessments up to
4 weeks before the planned first dose of selumetinib. Sub-
sequent tumor assessments were conducted prior to the
third cycle, every alternate cycle thereafter, and on with-
drawal of treatment.
EGFR and KRAS mutation analyses
Mutation status was an exploratory endpoint and an
optional part of the protocol. DNA was extracted from
formalin-fixed paraffin-embedded tissue samples using the
Cobas™ DNA Sample Preparation kit (Roche Molecular
Systems Inc., Pleasanton, CA, USA). Plasma DNA was
extracted using a non-commercial plasma preparation kit
supplied by Roche. DNA was assayed using the Cobas™
KRAS Mutation Test and Cobas™ EGFR Mutation Test
(Roche) according to the manufacturer’s protocols. The
EGFR mutation assay covered the following mutations:
exon 18 G719X (G719A, G719C, and G719S); exon 19 de-
letions and complex mutations; exon 20 S768I, T790M,
and insertions; and exon 21 L858R. The KRAS mutation
assay covered mutations in codons 12, 13 (exon 2), and 61
(exon 3). Data were generated and analysed using the
Cobas z480.
Statistical analysis
Three populations were defined for analysis: safety popu-
lation, evaluable for dose escalation (part A), and evaluable
for PK analysis. The safety population included all patients
who received one or more doses of selumetinib and
chemotherapy. Patients were considered evaluable for
dose escalation if they had received approximately 80% of
the planned doses of selumetinib in cycle 1, provided PK
data, and had all safety evaluations performed or experi-
enced a DLT, or at the discretion of the SRC. Patients who
could not complete 80% of planned doses or had to drop
out due to toxicity were considered DLT evaluable. The
evaluable for PK analysis population included all patients
with concentration-time data available.
No formal statistical hypothesis testing was performed
on the data; all data reported are based on summary statis-
tics: frequency counts and percentages for categorical data
and mean, median, range, standard deviation, geometric
mean, and % co-efficient of variation for continuous data
as appropriate.
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Results
Patient characteristics and disposition
A total of 35 patients received selumetinib plus docetaxel
and 25 patients received selumetinib plus dacarbazine.
The disposition of patients receiving selumetinib plus
docetaxel or selumetinib plus dacarbazine is summarized
in Fig. 1.
Among patients who received selumetinib plus doce-
taxel, 22 were treated in the dose-escalation phase (part
A); seven patients received selumetinib 50 mg BID plus
docetaxel and 15 patients received selumetinib 75 mg
BID plus docetaxel. Thirteen patients were included in
the dose expansion phase (part B), and received selume-
tinib 75 mg BID plus docetaxel. One patient from part A
and two from part B (all receiving selumetinib 75 mg
BID) remained on treatment at the time of the data cut-
off (August 2010).
Thirteen patients were treated with selumetinib plus
dacarbazine in the dose-escalation phase (part A); seven
patients received selumetinib 50 mg BID plus dacarbazine
and six patients received selumetinib 75 mg BID plus
dacarbazine. Twelve patients were included in the dose-
expansion phase (part B), receiving selumetinib 75 mg
BID plus dacarbazine. Two patients, both from part B,
remained on treatment at the time of the data cut-off.
Baseline characteristics in the overall study population
were typical of patients with advanced solid tumors
(Table 1).
Selumetinib in combination with docetaxel
Dose-limiting toxicities
In part A, there were no DLTs in patients receiving selu-
metinib 50 mg BID plus docetaxel. As local differences
in the use of ppG-CSF emerged during the study, pa-
tients treated with selumetinib 75 mg BID plus docetaxel
were stratified into two subgroups for analysis: patients
who did or did not receive ppG-CSF during cycle 1.
There were no DLTs in seven patients treated with selu-
metinib 75 mg BID plus docetaxel with ppG-CSF. Two
of eight patients receiving selumetinib 75 mg BID plus
docetaxel without ppG-CSF experienced DLTs (grade 4
febrile neutropenia and grade 4 thrombocytopenia)
(Table 2). Selumetinib 75 mg BID plus docetaxel with
ppG-CSF was defined as the MTD in part A.
In part A, it became apparent that patients treated
with selumetinib 75 mg BID plus docetaxel with (n = 7)
or without (n = 8) ppG-CSF had been heavily pretreated
(median of five or seven prior systemic therapies,
respectively). The SRC therefore recommended that part
B (dose expansion) should evaluate a patient population
similar to that planned in phase II studies and explore
the tolerability of administering selumetinib 75 mg BID
plus docetaxel without ppG-CSF. Thus, the part B ex-
pansion cohort enrolled less heavily pretreated patients
(median of 2.5 [range 1–7] prior systemic therapies) who
received selumetinib 75 mg BID plus docetaxel without
ppG-CSF, but with G-CSF allowed from cycle 2 onwards.
Febrile neutropenia and grade 4 neutropenia occurred in
two of 13 patients in part B. The combination of selu-
metinib 75 mg BID plus docetaxel without ppG-CSF
was considered to be tolerable in this less heavily treated
patient population.
Exposure
Patients in part B received the MTD of selumetinib
75 mg BID plus docetaxel for a median duration of ap-
proximately 5 months and 54% of these patients received
six or more (21-day) cycles of docetaxel. Long-term
follow-up reported that as of June 2015, two patients
with skin/soft tissue tumors had received 12 months of
combination treatment, and were continuing to receive
selumetinib monotherapy at reduced doses (one at
50 mg BID; one at 25 mg BID), both >6 years after first
receiving selumetinib. The remaining patient who was
still receiving study treatment at data cut-off was with-
drawn from the study in September 2010.
Tolerability
Diarrhea, peripheral edema, fatigue, nausea, vomiting,
rash, and neutropenia were the most commonly reported
AEs among patients receiving selumetinib plus docetaxel
(Table 3). AEs had a similar frequency across the dose
cohorts and were mostly grade 1 or 2. The most com-
monly reported grade ≥3 AEs across all dose groups were
neutropenia (15/35 patients, 43%), fatigue (7/35, 20%),
and febrile neutropenia (5/35, 14%). Grade 4 events of
neutropenia (>5 days) and febrile neutropenia were re-
ported in 11/28 (39%) and 2/28 (7%) patients receiving
selumetinib 75 mg BID plus docetaxel, respectively. Grade
5 AEs of pneumonia and febrile neutropenia were re-
ported in a patient with esophageal cancer while receiving
post-progression chemotherapy with FOLFIRI; neither AE
was considered by the investigator to be related to study
treatment.
Six patients (17%) experienced AEs relating to vision
disturbance, all of which were grade 1. Five patients
(14%) reported blurred vision (7 events in total) and 1
patient (3%) receiving selumetinib 75 mg BID without
ppG-CSF experienced reduced visual acuity. These AEs
are known to have resolved on continuing selumetinib for
5 of the 6 patients, with resolution in the remaining
patient unknown. One event of blurred vision was consid-
ered related to selumetinib, and one related to selumetinib
and docetaxel. AEs related to cardiac disorders were
reported in two patients who received selumetinib 75 mg
BID: one patient had grade 1 first degree atrioventricular
block and another patient had grade 2 cardiac valve dis-
ease which was identified 5 days after an SAE of
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Fig. 1 Patient disposition at the time of data cut-off for primary safety analysis (August 2010) in the (a) selumetinib plus docetaxel and
(b) selumetinib plus dacarbazine treatment arms. BID, twice daily; ppG-CSF, primary prophylactic granulocyte-colony stimulating factor
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pulmonary hypertension. There were no AEs related to
left ventricular ejection fraction (LVEF).
In part A of this study, the incidences of grade ≥3
neutropenia and grade ≥3 febrile neutropenia in pa-
tients who received selumetinib 75 mg BID plus do-
cetaxel were lower in those who received ppG-CSF
(1/7 patients, 14% and 0%, respectively) compared
with those who did not receive ppG-CSF (5/8, 63%
and 3/8, 38%, respectively). With selumetinib 75 mg
BID plus docetaxel, one patient (14.3%) also receiving
ppG-CSF required a dose reduction of selumetinib,
whereas three patients who did not receive ppG-CSF
required at least one dose reduction of selumetinib.
In part B, six patients who received selumetinib
75 mg plus docetaxel without ppG-CSF required a
selumetinib dose reduction.
Table 1 Baseline characteristics of patients
Characteristics, n (%) Selumetinib + docetaxel (N = 35) Selumetinib + dacarbazine (N = 25)
Age, years; mean (SD) 58.9 (9.5) 57.1 (11.5)
Male 21 (60.0) 15 (60.0)
Female 14 (40.0) 10 (40.0)
Race
White 33 (94.3) 25 (100.0)
Black/African American 2 (5.7) 0
WHO performance status
0 14 (40.0) 12 (48.0)
1 21 (60.0) 13 (52.0)
Primary tumor site
Skin/soft tissue 11 (31.4) 17 (68.0)
Lung 8 (22.9) 3 (12.0)
Breast 3 (8.6) 0
Colorectal 2 (5.7) 0
Esophagus 2 (5.7) 0
Ovary 2 (5.7) 0
Head and neck 1 (2.9) 1 (4.0)
Uveal 1 (2.9) 1 (4.0)
Othera 5 (14.3) 3 (12.0)
Mean prior systemic treatments 3.1 2.0
Prior therapy, n (%)
Chemotherapy 30 (85.7) 18 (72.0)
Platinum compounds 24 (68.6) 9 (36.0)
Taxanes 18 (51.4) 8 (32.0)
Pyrimidine analogues 6 (17.1) 1 (4.0)
Anthracyclines 5 (14.3) 3 (12.0)
Radiotherapy 18 (51.4) 13 (52.0)
Other systemic anticancer therapyb 8 (22.9) 8 (32.0)
Immuno/hormonal therapy 6 (17.1) 0
Hormonal therapy 3 (8.6) 0
Immunotherapy 2 (5.7) 10 (40.0)
Prior lines of chemotherapy, n (%)
0 or 1 17 (48.6) 21 (84.0)
2 or 3 10 (28.6) 2 (8.0)
4+ 8 (22.9) 2 (8.0)
aIncludes bladder, lymph nodes, melanoma, muscle, prostate, pancreas, stomach, unknown primary, and uterus
bIncludes monoclonal antibodies, vaccines, small molecule targeted agents, and investigational drugs
SD, standard deviation; WHO, World Health Organization
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Pharmacokinetics analysis
Pharmacokinetic parameters of selumetinib, N-desmethyl
selumetinib, and docetaxel (summarized in Table 4)
were similar when administered alone and in combin-
ation. Plasma concentration time profiles of selumetinib,
N-desmethyl selumetinib, and docetaxel were also similar
when administered alone or in combination (Additional
file 2: Figure S1).
Tumor response
Six of 27 evaluable patients receiving selumetinib plus
docetaxel had a confirmed partial response (melanoma,
n = 2; lung, head and neck, ovarian, unknown primary,
n = 1 each); KRAS or EGFR mutations were not detected
in these patients. An additional 14 patients had a best
response of stable disease ≥6 weeks, including two pa-
tients (one with lung cancer, one with bladder cancer)
who had unconfirmed partial responses. Seven patients
had progressive disease as best response. At week 12, 11
patients (31.4%) had stable disease and five patients
(14.3%) had an objective response. The median duration
of response in patients receiving selumetinib 75 mg BID
plus docetaxel was 328 days (range 95 to 555). Greatest
change from baseline (n = 26) in target lesion size is
presented in Fig. 2.
Selumetinib in combination with dacarbazine
Dose-limiting toxicities
Seven patients received selumetinib 50 mg BID plus
dacarbazine, and one of six evaluable patients had a DLT
(grade 4 thrombocytopenia). DLTs did not occur in the
other selumetinib plus dacarbazine dose cohorts and
selumetinib 75 mg BID plus dacarbazine was defined as
the MTD in part A.
Exposure
For patients who received selumetinib 75 mg BID plus
dacarbazine, the mean duration of selumetinib treatment
was approximately 6 months, and 44% of patients had
combination treatment for six or more (21-day) cycles.
Two patients with lymph node or skin/soft tissue tumors
who were ongoing at the time of data cut-off received
selumetinib treatment for >18 months (2 years 9 months
and 1 year 7 months, respectively) before discontinuing
study treatment.
Tolerability
Diarrhea, peripheral/periorbital edema, nausea, and fa-
tigue were the most commonly reported AEs among pa-
tients receiving selumetinib plus dacarbazine (Table 3).
The most commonly reported grade ≥3 AEs were:
anemia (4/25 patients, 16%), neutropenia (3/25, 12%), fa-
tigue (3/25, 12%), and thrombocytopenia (2/25, 8%).
With the exception of fatigue, non-hematologic grade ≥3
AEs were not reported in more than one patient.
Eleven patients (44%) experienced grade 1 AEs relating
to vision disturbance. Seven patients (28%) reported
blurred vision and four patients (16%) had vitreous
floaters. AEs related to cardiac disorders were reported in
two patients (8%) receiving selumetinib 75 mg BID; one
patient (4%) had grade 2 left ventricular dysfunction that
was considered related to selumetinib by the investigator
and resolved, and one patient had grade 1 electrocardio-
gram QT prolongation, for which the investigator tempor-
arily stopped treatment.
In part A, one patient each from the selumetinib
50 mg BID plus dacarbazine (14.3%) and selumetinib
75 mg BID plus dacarbazine (16.7%) arms required a
dose reduction of selumetinib. One patient (8.3%)
Table 2 Summary of cohorts and dose escalation based on dose-limiting toxicity





Selumetinib in combination with docetaxel
A 50 mg BID 7 (6) 0 NA
75 mg BID with ppG-
CSF
7 (6) 0 NA
75 mg BID without
ppG-CSF
8 (5) 2 Grade 4 neutropenia with fever (n = 1) Grade 4
thrombocytopenia (n = 1)
B 75 mg BID with ppG-
CSF
12 (NA) NA NA
75 mg BID without
ppG-CSF
1 (NA) NA NA
Selumetinib in combination with dacarbazine
A 50 mg BID 7 (6) 1 Grade 4 thrombocytopenia (n = 1)
75 mg BID 6 (6) 0 NA
B 75 mg BID 12 (NA) NA NA
BID, twice daily; DLT, dose-limiting toxicity; NA, not applicable; ppG-CSF, primary prophylactic granulocyte-colony stimulating factor
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Table 3 Adverse events: selumetinib in combination with docetaxel or dacarbazine
Part A Part B Part A + B
Selumetinib 50 mg
BID (N = 7)
Selumetinib 75 mg BID
with ppG-CSF (N = 7)
Selumetinib 75 mg BID
without ppG-CSF (N = 8)
Selumetinib 75 mg
BIDa (N = 13)
Selumetinib 75 mg
BID (N = 28)
Selumetinib in combination with docetaxel AE category, n (%)
Any AE 7 (100.0) 7 (100.0) 8 (100.0) 12 (92.3) 27 (96.4)
Any grade ≥3 AE 5 (71.4) 1 (14.3) 7 (87.5) 11 (84.6) 19 (67.9)
Any SAE 4 (57.1) 2 (28.6) 5 (62.5) 7 (53.8) 14 (50.0)
Any AE leading to
discontinuation
0 0 0 2 (15.4) 2 (7.1)
Most frequently reported AEs (≥20% of patients receiving selumetinib 75 mg BID + docetaxel), n (%)
Diarrhea 5 (71.4) 3 (42.9) 7 (87.5) 11 (84.6) 21 (75.0)
Edema peripheral 5 (71.4) 3 (42.9) 7 (87.5) 10 (76.9) 20 (71.4)
Fatigue 7 (100.0) 2 (28.6) 5 (62.5) 9 (69.2) 16 (57.1)
Nausea 2 (28.6) 3 (42.9) 4 (50.0) 8 (61.5) 15 (53.6)
Vomiting 4 (57.1) 3 (42.9) 4 (50.0) 5 (38.5) 12 (42.9)
Dermatitis
acneiform
3 (42.9) 4 (57.1) 3 (37.5) 5 (38.5) 12 (42.9)
Neutropenia 4 (57.1) 1 (14.3) 5 (62.5) 5 (38.5) 11 (39.3)
Constipation 3 (42.9) 2 (28.6) 3 (37.5) 4 (30.8) 9 (32.1)
Dyspnea exertional 3 (42.9) 1 (14.3) 2 (25.0) 5 (38.5) 8 (28.6)
Epistaxis 3 (42.9) 2 (28.6) 2 (25.0) 4 (30.8) 8 (28.6)
Dysgeusia 2 (28.6) 2 (28.6) 1 (12.5) 5 (38.5) 8 (28.6)
Neuropathy
peripheral
2 (28.6) 2 (28.6) 3 (37.5) 3 (23.1) 8 (28.6)
Mucosal
inflammation
5 (71.4) 3 (42.9) 1 (12.5) 2 (15.4) 6 (21.4)
Nail disorder 1 (14.3) 1 (14.3) 3 (37.5) 2 (15.4) 6 (21.4)
Selumetinib in combination with dacarbazine AE category, n (%)
Any AE 7 (100.0) 6 (100.0) 12 (100.0) 18 (100.0)
Any grade ≥3 7 (100.0) 2 (33.3) 9 (75.0) 11 (61.1)
Any SAE 4 (57.1) 2 (33.3) 4 (33.3) 6 (33.3)
Any AE leading to
discontinuation
0 0 1 (8.3) 1 (5.6)
Most frequently reported AEs (≥30% of patients receiving selumetinib 75 mg BID + dacarbazine), n (%)
Diarrhea 4 (57.1) 6 (100.0) 9 (75.0) 15 (83.3)
Nausea 5 (71.4) 5 (83.3) 10 (83.3) 15 (83.3)
Fatigue 2 (28.6) 3 (50.0) 11 (91.7) 14 (77.8)
Decreased appetite 1 (14.3) 3 (50.0) 8 (66.7) 11 (61.1)
Dizziness 1 (14.3) 2 (33.3) 8 (66.7) 10 (55.6)
Headache 1 (14.3) 4 (66.7) 6 (50.0) 10 (55.6)
Vomiting 1 (14.3) 3 (50.0) 7 (58.3) 10 (55.6)
Constipation 3 (42.9) 3 (50.0) 6 (50.0) 9 (50.0)
Dermatitis
acneiform
1 (14.3) 2 (33.3) 7 (58.3) 9 (50.0)
Edema peripheral 3 (42.9) 1 (16.7) 8 (66.7) 9 (50.0)
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receiving selumetinib 75 mg BID plus dacarbazine in
part B required a selumetinib dose reduction.
One patient with uterine cancer and lung and pleural
metastases had grade 4 AEs of malignant pleural effusion
and exertional dyspnea 34 days after starting treatment
with selumetinib 50 mg BID plus dacarbazine. These
events were considered by the investigator to be related to
disease progression and not to study treatment. The pri-
mary cause of death was reported as fatal AEs of dyspnea
exertional and malignant pleural effusion.
Pharmacokinetics analysis
Pharmacokinetic parameters of selumetinib, N-desmethyl
selumetinib, dacarbazine, and 5-aminoimidazole-4-car-
boxamide (main metabolite of dacarbazine) were similar
when administered alone and in combination (summa-
rized in Table 4). Plasma concentration-time profiles of
selumetinib, N-desmethyl selumetinib, and dacarbazine
were also similar when administered alone or in combin-
ation (Additional file 3: Figure S2).
Tumor response
Four of 23 evaluable patients receiving selumetinib plus
dacarbazine had a confirmed partial response (melanoma,
n = 3; unknown primary cancer, n = 1) and 15 had a best
response of stable disease ≥6 weeks (including one patient
with a skin/soft tissue tumor and one with lung cancer
who had unconfirmed partial responses). Six patients had
progressive disease. None of the responding patients had
primary tumor and/or plasma samples available for
mutation analysis. At week 12, seven patients had stable
disease, and two patients had an objective response. The
median duration of response in patients receiving 75 mg
BID plus dacarbazine was 245.5 (range 73 to 308) days.
Greatest change from baseline in target lesion size is
presented in Fig. 2.
Discussion
At the time of study initiation, data from preclinical stud-
ies suggested that selumetinib in combination with a var-
iety of DNA-damaging agents and molecularly targeted
therapies may enhance anti-tumor efficacy compared with
single agent administration [1, 11]. Combinations with
docetaxel and dacarbazine have since shown clinical activ-
ity in phase II trials [12, 13].
This phase I study was the basis for establishing the
safety, tolerability, MTD, and PK of selumetinib BID in
combination with standard doses of two commonly used
cytotoxic chemotherapeutic drugs in patients with ad-
vanced solid tumors. Data from patients who received
selumetinib in combination with erlotinib or temsirolimus
are presented in the companion paper (Infante et al., in
preparation).
Selumetinib was tolerable in combination with docetaxel
or dacarbazine. As with the monotherapy recommended
phase II dose [4], we determined that the MTD of selumeti-
nib was 75 mg BID when administered with standard doses
of docetaxel 75 mg/m2 without ppG-CSF or with dacarba-
zine 1000 mg/m2. Consistent with our expectations,
combination treatment reported here did not affect expos-
ure to docetaxel, dacarbazine, or to selumetinib and its
metabolite N-desmethyl selumetinib [6, 15, 16].
The tolerability of selumetinib in combination with doce-
taxel or dacarbazine was broadly consistent with the safety
profiles of the individual regimen components [9, 17–19].
AEs that occurred most frequently with either combin-
ation were diarrhea, peripheral/periorbital edema, fatigue,
nausea, and vomiting. Only a limited number of patients
had ophthalmologic or LVEF assessments on study, so no
definitive conclusions could be made relating to these
domains.
The tolerability profiles in this phase I study have been
seen in subsequent placebo-controlled, phase II trials of
selumetinib plus dacarbazine in patients with treatment-
naïve BRAF-mutant metastatic melanoma and selumetinib
plus docetaxel in pretreated patients with KRAS-mutant
advanced NSCLC [12, 13]. In both trials, the most
frequently reported AEs for selumetinib combination
arms were nausea, acneiform dermatitis, diarrhea, vomi-
ting, and peripheral edema.
We determined a recommended phase II dose of selu-
metinib 75 mg BID plus docetaxel without ppG-CSF.
However, in two phase II studies of selumetinib plus doce-
taxel without ppG-CSF for patients with treatment-naïve
advanced melanoma and pretreated KRAS-mutant
advanced NSCLC, increased incidences of grade ≥3 febrile
neutropenia were reported compared with placebo (21%
Table 3 Adverse events: selumetinib in combination with docetaxel or dacarbazine (Continued)
Dyspnea exertional 1 (14.3) 2 (33.3) 6 (50.0) 8 (44.4)
Asthenia 0 2 (33.3) 5 (41.7) 7 (38.9)
Vision blurred 0 1 (16.7) 6 (50.0) 7 (38.9)
Periorbital edema 1 (14.3) 0 6 (50.0) 6 (33.3)
Docetaxel, 75 mg/m2; dacarbazine 1000 mg/m2
appG-CSF allowed from cycle 2 onwards
AE, adverse event; BID, twice daily; ppG-CSF, primary prophylactic granulocyte-colony stimulating factor; SAE, serious adverse event
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vs. 12% and 18% vs. 0%, respectively) [12, 20]. The reason
for this discrepancy likely derives from the inaccuracy of
many recommended phase II dose determinations based
on studies of a relatively small number of carefully selected
patients treated at phase I research centres. Two subse-
quent multicenter trials of selumetinib plus docetaxel for
patients with advanced NSCLC included mandatory
administration of ppG-CSF in the protocol: SELECT-1,
evaluating the combination as second-line treatment in
KRAS-mutant advanced NSCLC (ClinicalTrials.gov identi-
fier: NCT01933932); and SELECT-2, evaluating the hypoth-
esis that clinical activity of the combination is not limited
to patients with advanced NSCLC that harbours KRAS
mutations (ClinicalTrials.gov identifier: NCT01750281).
Although this study was not designed to assess clin-
ical efficacy, objective tumor responses were reported
in some patients. Among evaluable patients receiving
selumetinib plus docetaxel, 6/27 (22%) had a con-
firmed partial response and an additional 14/27 (52%)
had stable disease ≥6 weeks. At week 12, 11 (31%)
patients had stable disease and five (14%) patients
had an objective response. Interestingly, KRAS or
EGFR mutations were not detected in any of the pa-
tients who responded, supporting the hypothesis
under investigation in the SELECT-2 trial. Confirmed
partial responses occurred in 4/23 (17%) evaluable
patients receiving selumetinib plus dacarbazine and
15/23 (65%) had stable disease ≥6 weeks. At week 12,
Fig. 2 Waterfall plots for greatest change in target lesion size from baseline for the (a) selumetinib plus docetaxel and (b) selumetinib plus
dacarbazine arms. Lower reference line indicates the point below which best response is partial response (>30% reduction). Upper reference line
indicates the point above which best response is progressive disease (>20%). Administration of primary prophylactic granulocyte colony stimulating
factor (ppG-CSF) differed between the part A selumetinib 75 mg bid cohort due to differences in treatment practices between study centers:
aReceived primary ppG-CSF in cycle 1; bDid not receive ppG-CSF in cycle 1. Response Evaluation Criteria In Solid Tumors best response: N, not evalu-
able; P, progressive disease; R, partial response; S, stable disease. Population: Measurable disease at baseline and underwent follow-up scan
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seven (28%) patients had stable disease, and two (8%)
patients had an objective response.
Conclusion
Selumetinib 75 mg BID in combination with dacarbazine
or docetaxel (plus ppG-CSF as appropriate) demonstrated
clinical activity and was reasonably well tolerated in pa-
tients with advanced solid tumors, informing further
evaluation in randomized studies.
Additional files
Additional file 1: Table S1. Independent Ethics Committees/
Institutional Review Boards consulted (DOCX 42 kb)
Additional file 2: Figure S1. Plots of geometric mean (+/− standard
deviation) plasma concentrations over time of (A) selumetinib 75 mg BID
alone and in combination with docetaxel 75 mg/m2 or (B) docetaxel
75 mg/m2 alone and in combination with selumetinib 75 mg BID (EPS
1929 kb)
Additional file 3: Figure S2. Plots of geometric mean (+/− standard
deviation) plasma concentrations over time of (A) selumetinib 75 mg BID
alone and in combination with dacarbazine 1000 mg/m2 or (B)
dacarbazine 1000 mg/m2 alone and in combination with selumetinib
75 mg BID (EPS 1925 kb)
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